Articles tagged with Ovarian Cancer
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
A 'master regulator' gene, ZNFX1, has been identified that may help guide treatment in patients with therapy-resistant ovarian cancer. The expression of this biomarker correlates with improved survival outcomes.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A novel subset of progenitor cells, called high-risk MSCs, reside in the stroma and promote DNA damage and tumor growth. These cells play a critical role in the initiation of ovarian cancer, particularly in older women or those with BRCA mutations.
Researchers found that Black women have nearly identical mutations to other populations but experience lower survival rates due to clinical factors. The study highlights the importance of studying different population groups to improve ovarian cancer healthcare and develop targeted treatments.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers found that women who had used the oral contraceptive pill had a lower risk of ovarian cancer, with a 39% reduced risk for those who had given birth to two or more children. The study also identified certain biomarkers and lifestyle factors associated with a lower risk of ovarian cancer, including lower body weight and short...
A mathematical modeling study suggests that removing fallopian tubes during other abdominal surgeries can lower ovarian cancer incidence by five percent. The approach could also reduce total healthcare costs in Germany, with estimated annual savings of over €10 million.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
Genetic testing for cancer risk should always include healthcare providers and genetic counseling to ensure users fully understand their results and receive proper guidance. The authors call on the FDA to provide clear rules for using these tests, particularly for minors.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
A new MRI-based imaging technique can rapidly assess ovarian cancer subtypes and their response to treatment, allowing for personalized treatment planning. The technique, called hyperpolarised carbon-13 imaging, distinguishes between two different subtypes of ovarian cancer and reveals their sensitivities to treatment.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
Researchers discovered that ovarian cancer produces IL-4 to create a protective environment, resisting immunotherapy. Blocking IL-4 with dupilumab-like drugs could enhance immunotherapy for ovarian cancer.
Researchers discovered a mechanism used by ovarian tumors to cripple immune cells by blocking the energy supply T cells depend on. The discovery points toward a promising new immunotherapy approach for treating ovarian cancer.
The researchers aim to establish targets for the vaccine by identifying proteins on the surface of early-stage ovarian cancer cells recognized by the immune system. If successful, clinical trials will begin to test the vaccine's effectiveness in preventing ovarian cancer, potentially offering a solution for women at high risk.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A blood test combining AI, cell-free DNA, and protein biomarkers shows high accuracy in detecting ovarian cancer. The test distinguishes between benign growths and cancerous tumors, offering a potential affordable screening method for widespread use.
Researchers identified over 3,000 harmful genetic changes in the RAD51C gene that increase ovarian cancer risk six-fold and breast cancer risk four-fold. These findings can help doctors and diagnostic laboratory scientists better assess cancer risk and provide more personalized care.
A recent study found that Chinese patients with ovarian cancer often carry a specific variant of the RAD51D gene, which can promote tumor growth. The variant also makes these patients more sensitive to PARP inhibitors, leading to a favorable prognosis and potential new treatment methods.
Researchers analyzed data from 1741 women diagnosed with high-grade serous ovarian cancer and found that symptom-triggered testing can lead to diagnosis of low-disease spread cases. In most cases, complete surgical removal of the cancerous tissue was possible, challenging the assumption that symptoms always signal advanced disease.
Researchers found that symptom-triggered testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected. The UK's protocol for picking up early-stage disease is an effective way to diagnose even early-stage ovarian cancer, with complete surgical removal possible in more than three quarters of women.
A study by the University of Gothenburg finds that removing Fallopian tubes during laparoscopic sterilization results in marginally more surgical complications than cutting them. The procedure may help protect against future ovarian cancer, a serious disease with limited early symptoms.
Researchers found that abnormal results from routine blood tests were linked to a higher risk of being diagnosed with cancer within a year. The study estimated that taking these results into account could lead to an extra six people with undiagnosed cancer being urgently referred for treatment.
A preclinical study led by Weill Cornell Medicine researchers found that the iron-chelating drug deferiprone can selectively target and kill ovarian cancer cells. By starving cancer cells of iron, deferiprone triggers a cellular stress response, prompting the immune system to attack them.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
A landmark study found women with severe endometriosis have a 10-fold increased risk of ovarian cancer, compared to those without the disease. The study analyzed over 78,000 women and revealed that those with severe endometriosis are also at higher risk for type I ovarian cancer.
Researchers at Dana-Farber Cancer Institute have developed CAR memory-like NK cells targeting the mesothelin protein, demonstrating superior antitumor activity in laboratory and animal models. The new cells maintained their effectiveness even after exposure to immunosuppressive ascitic fluid.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
Researchers at Wayne State University aim to develop improved treatments for ovarian cancer by targeting dual-specificity phosphatase 1, a protein involved in drug resistance. The four-year grant will support the study's efforts to improve survival and remission rates.
Research links early menopause to higher risks of breast and ovarian cancer in women. Second-degree relatives also show increased risks for colon, prostate, and testicular cancers.
Researchers found that adding BRCA1 testing to prenatal carrier screening is cost-effective and can identify at-risk individuals before they develop cancer. The study simulated a cohort of pregnant patients and found that this approach could prevent 1,394 breast and ovarian cancer cases and 1,084 fewer deaths.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
This meta-analysis evaluated the diagnostic performance of three-dimensional power Doppler (3DPD) for detecting ovarian cancer in adnexal masses. The results show that 3DPD has good sensitivity and specificity, particularly in complex or suspicious masses. However, it does not add significant value to current 2D US-based approaches.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
A plant virus treatment, composed of cowpea mosaic virus nanoparticles, has shown remarkable success in improving survival rates and suppressing the growth of metastatic tumors across various cancer models. The treatment was effective even after surgical removal of tumors, indicating its potential to prevent metastasis.
A large-scale study of 572 Asian families with BRCA1 and BRCA2 mutations found increased breast cancer risk over time, with highest incidence at age 55. The study provides a new framework for estimating cancer risks in Asian carriers, supporting tailored clinical management approaches.
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
A recent study investigated the causal relationships between sarcopenia-related traits, body mass index (BMI), and ovarian cancer risk. The research found that slower usual walking pace was associated with lower ovarian cancer risk, while high appendicular lean mass and high BMI were linked to increased risk. These findings highlight a...
A new machine learning assay combines cell-free DNA fragment patterns and protein biomarkers to differentiate patients with ovarian cancer from healthy controls. The approach has shown high accuracy in detecting the disease, outperforming current biomarkers.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
A new study from Uppsala University found that women with germ cell tumors have a significantly lower five-year survival rate (85.2%) compared to men (98.2%). The researchers suggest that concentrating patients in fewer hospitals and using treatment strategies for testicular cancer could improve survival rates and reduce side effects.
Researchers at Johns Hopkins Kimmel Cancer Center and University School of Medicine developed an algorithm, REAL-FAST, to identify high-risk precancerous lesions on the fallopian tubes. The test accurately detected cancer 95.8% of the time and correctly ruled out cancer 97.1% of the time.